346 KEYNOTE-991: phase 3 study of pembrolizumab plus enzalutamide and androgen deprivation therapy (ADT) for patients with metastatic hormone-sensitive prostate cancer (mHSPC)

• Christian Poehlein,
• Joseph Burgents,
• Christian Gratzke,
• Cuizhen Niu

Affiliations

Christian Poehlein

Aff400 grid.417993.10000000122600793Merck & Co., Inc. Kenilworth NJ USA

Joseph Burgents

2Merck and Co., Inc., Kenilworth, NJ, USA

Christian Gratzke

1University Medical Center Freiburg, Freiburg, Germany

Cuizhen Niu

2MSD China, Beijing, China